Johnson & Johnson’s consumer health business Kenvue Inc. raised $3.8 billion in an upsized initial public offering that is the biggest US listing since 2021.
(Bloomberg) — Johnson & Johnson’s consumer health business Kenvue Inc. raised $3.8 billion in an upsized initial public offering that is the biggest US listing since 2021.
Kenvue’s IPO price of $22 per share, which confirmed an earlier Bloomberg News report, is in the top half of the company’s marketed range of $20 to $23 each.
The company also expanded the number of shares it’s selling to 172.8 million from 151 million, according to a press release, giving Kenvue a market value of more than $41 billion.
The listing follows the slowest start to a year for US IPOs since 2016, according to data compiled by Bloomberg News.
Kenvue’s products include dozens of J&J brands that are household names, including Tylenol, Listerine, Neutrogena and Nicorette. On a pro forma basis, the business had net income of about $1.5 billion on sales of almost $15 billion for the year ended Jan. 1, according to its filings.
J&J, with a market value of more than $426 billion, has been saddled with thousands of lawsuits alleging talc in Johnson’s baby powder cause cancer. That’s contributed to a 9.8% decline in its share price in the past year in contrast to the 1% gain in the S&P 500 Health Care Index. While J&J is retaining liability for the talc cases, Kenvue has already been sued over talc-injury claims and has cautioned that it may be subject to claims arising outside the US and Canada.
Kenvue’s IPO is being led by Goldman Sachs Group Inc., JPMorgan Chase & Co. and Bank of America Corp. Its shares are expected to begin trading Thursday on the New York Stock Exchange under the symbol KVUE.
(Updates throughout with attribution from press release.)
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.